How long does Kawasaki disease require hospitalization?

Written by Yan Xin Liang
Pediatrics
Updated on February 23, 2025
00:00
00:00

Kawasaki disease is an autoimmune vasculitis, primarily concerning because it affects the coronary arteries of the heart. Without effective treatment, some cases can lead to coronary artery dilation and even the formation of coronary artery aneurysms. Therefore, hospitalization is generally recommended during the acute phase of Kawasaki disease. During hospitalization, treatment typically involves the use of intravenous immunoglobulin and aspirin. After treatment with intravenous immunoglobulin, the body temperature generally begins to decrease gradually. Once the body temperature has stabilized for about three days and there are no complications, the patient can usually be discharged, so most hospital stays last about 5-7 days. (Medication should be taken under the guidance of a doctor.)

Other Voices

doctor image
home-news-image
Written by Yan Xin Liang
Pediatrics
52sec home-news-image

Is Kawasaki disease characterized by eye discharge?

Kawasaki disease is an autoimmune vasculitis that can affect blood vessels throughout the body and various organs, but the most severe impact is typically on the coronary arteries, which can lead to dilation of the coronary arteries or the possibility of forming coronary artery aneurysms. The disease can cause conjunctival congestion, but this is a manifestation of aseptic conjunctivitis, meaning it does not cause, nor does it result in, purulent secretions, in other words, it does not cause eye discharge. Therefore, if a patient with Kawasaki disease has purulent eye discharge, it is possible that they have a concurrent bacterial conjunctivitis. Thus, generally, eyes affected by Kawasaki disease do not have eye discharge but may appear dry and red.

doctor image
home-news-image
Written by Li Jiao Yan
Neonatology
48sec home-news-image

Is IgE high in Kawasaki disease?

Kawasaki disease, also known as mucocutaneous lymph node syndrome, has an unclear pathogenesis. It is speculated that certain components of infectious sources, such as superantigens, can activate CD30 T cells and CD40 ligand expression directly by binding with T cell antigen receptor fragments without going through mononuclear macrophages. Under the induction of carrier cells, there is polyclonal activation and reduced apoptosis of B08 cells, resulting in the production of large amounts of immunoglobulins such as IgG, IgM, IgA, and IgE, and cytokines. Therefore, the IgE levels in Kawasaki disease are elevated.

doctor image
home-news-image
Written by Yao Li Qin
Pediatrics
46sec home-news-image

Kawasaki disease incubation period

Kawasaki disease, also known as mucocutaneous lymph node syndrome, is a common pediatric fever and rash illness, primarily a systemic small vessel vasculitis. Kawasaki disease is not contagious, so it has no incubation period; only infectious diseases have incubation periods. If it were contagious, typical manifestations would include persistent high fever, pinpoint appearances around the eyes and mouth, typical rash, swelling of the hands and feet, and non-purulent swelling of the cervical lymph nodes. Therefore, Kawasaki disease has no incubation period and is a vasculitis mediated by immune mechanisms.

doctor image
home-news-image
Written by Yan Xin Liang
Pediatrics
59sec home-news-image

Kawasaki disease sequelae

Kawasaki disease is an autoimmune vasculitis, and since it is vasculitis, it can originate from blood vessels in various parts, including the heart, liver, kidneys, brain, and more. However, it mainly arises from the coronary arteries of the heart. If Kawasaki disease is not effectively treated, some patients can develop coronary artery dilation and even coronary artery aneurysms. Once a coronary artery aneurysm occurs, its complication includes the risk of rupture and bleeding of the aneurysm, which can be difficult to treat if there is severe bleeding. If there is some coronary artery dilation, it can lead to the formation of coronary artery thrombosis, which is also a complication it can cause. However, the vast majority of Kawasaki disease cases, if treated effectively, can prevent coronary artery abnormalities. Therefore, as long as the treatment is timely, most cases will not have significant lasting effects.

doctor image
home-news-image
Written by Yao Li Qin
Pediatrics
1min 16sec home-news-image

How is Kawasaki disease treated?

Kawasaki disease, also known as mucocutaneous lymph node syndrome, can cause damage to the coronary arteries in untreated children, so it is crucial to treat the disease promptly once diagnosed. This disease generally occurs sporadically or in small outbreaks and can occur in any season, predominantly affecting infants and young children. The main treatment for Kawasaki disease is aspirin, which not only reduces fever but also helps reduce coronary artery lesions. Additionally, intravenous immunoglobulin is administered; however, the use of corticosteroids in Kawasaki disease is still somewhat controversial. Other treatments mainly include antiplatelet aggregation agents such as dipyridamole, and symptomatic supportive care for the child, including fluid supplementation, heart protection, control of heart failure, and correction of arrhythmias. For severe coronary artery lesions, coronary artery bypass surgery may be required. (Please use medication under the guidance of a professional physician.)